An update on the management of hepatitis C:

guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver 

Autores: Chavez Tapia Norberto Carlos, Ridruejo Ezequiel, Alves de Mattos Angelo, Bessone Fernando, Daruich Jorge, Sánchez Ávila Juan Francisco, Cheinquer Hugo, et al

Resumen

Hepatitis C is a common cause of end-stage liver disease, and the main indication for liver transplantation in Latin America. Treatment of hepatitis C infected patients improves important long-term outcomes as mortality. Sustained viral response is reached in near 50% of patients with the previous management based in pegylated interferon and ribavirin. Recently new drugs were available increasing sustained viral response significantly, changing the standard of care to triple therapy. This guidelines provides a framework for practitioner in Latin America, to the management of patients with hepatitis C chronic infection.

Palabras clave: Consensus therapeutics boceprevir liver diseases chronic hepatitis C telaprevir.

2013-04-03   |   680 visitas   |   Evalua este artículo 0 valoraciones

Vol. 12 Núm.2. Marzo-Abril 2013 Pags. 3-35 Ann Hepatol 2013; 12(Supl. 2)